anti-doping raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-02-10 and is reviewed periodically as new material appears.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Prohibited in sport | Listed by WADA under peptide hormones |
| WADA class | S2 | Peptide hormones, growth factors, related substances, and mimetics |
| Approved therapeutic use | Not established | Clinical research did not lead to broad marketing approval |
| Common detection method | LC-MS/MS | Liquid chromatography-tandem mass spectrometry |
| Sample preparation | Extraction and enrichment | Immunoaffinity or solid-phase extraction may be used |
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
In a hospital setting, sample processing will usually start with a set of samples arriving with a test request, either on a form or electronically via the laboratory information system (LIS). Inpatient specimens will already be labeled with patient and testing information provided by the LIS. Entry of test requests onto the LIS system involves typing (or scanning where barcodes are used) in the laboratory number, and entering the patient identification, as well as any tests requested. This allows laboratory analyzers, computers and staff to recognize what tests are pending, and also gives a location (such as a hospital department, doctor or other customer) for results reporting. Once the specimens are assigned a laboratory number by the LIS, a sticker is typically printed that can be placed on the tubes or specimen containers. This label has a barcode that can be scanned by automated analyzers and test requests uploaded to the analyzer from the LIS. Specimens are prepared for analysis in various ways. For example, chemistry samples are usually centrifuged and the serum or plasma is separated and tested. If the specimen needs to go on more than one analyzer, it can be divided into separate tubes. Many specimens end up in one or more sophisticated automated analysers, that process a fraction of the sample to return one or more test results. Some laboratories use robotic sample handlers (Laboratory automation) to optimize the workflow and reduce the risk of contamination from sample handling by the staff.
=== Liver === The liver parenchyma is the functional tissue of the organ made up of around 80% of the liver volume as hepatocytes. The other main type of liver cells are non-parenchymal. Non-parenchymal cells constitute 40% of the total number of liver cells but only 6.5% of its volume.
Benzodiazepines are sometimes used for criminal purposes; they serve to incapacitate a victim in cases of drug assisted rape or robbery. Overall, anecdotal evidence suggests that temazepam may be the most psychologically habit-forming benzodiazepine. Non-medical temazepam use reached epidemic proportions in some parts of the world, in particular, in Europe and Australia, and is a major addictive substance in many Southeast Asian countries. This led authorities of various countries to place temazepam under a more restrictive legal status. Some countries, such as Sweden, banned the drug outright. Temazepam also has certain pharmacokinetic properties of absorption, distribution, elimination, and clearance that make it more apt to non-medical use compared to many other benzodiazepines.
John Franklin Enders, who had shared the 1954 Nobel Prize in Medicine for work on the polio virus, sent Thomas C. Peebles to Fay School in Massachusetts, where an outbreak of measles was underway. Peebles was able to isolate the virus from blood samples and throat swabs. He later successfully cultivated the virus and showed that the disease could be passed on to monkeys inoculated with the material he had collected. Enders used the cultivated virus to develop a measles vaccine in 1963 by attenuation through cultured chicken embryo fibroblasts of the material isolated by Peebles. In the late 1950s and early 1960s, nearly twice as many children died from measles as from polio. The vaccine Enders developed was based on the Edmonston strain of attenuated live measles virus, which was named for 11-year-old David Edmonston, the Fay student from whom Peebles had taken the culture that led to the virus's cultivation. In the mid-20th century, measles was particularly devastating in West Africa, where child mortality rate was 50 percent before age five, and the children were struck with the type of rash and other symptoms common prior to 1900 in England and other countries. The first trial of a live attenuated measles vaccine was undertaken in 1960 by British paediatrician David Morley in a village near Ilesha, Nigeria; in case he could be accused of exploiting the Nigerian population, Morley included his own four children in the study. The encouraging results led to a second study of about 450 children in the village and at the Wesley Guild Hospital in Ilesha.
Sources: en.wikipedia.org
== Education and professional development == The HGSA oversees professional training and certification in the fields of Diagnostic Genomics and Genetic Counseling. Two Boards of Censors oversee training in these two respective fields. The HGSA partners with the Royal College of Pathologists of Australasia to train senior diagnostic genomicists to become Fellows of the Faculty of Science. The Australasian Association of Clinical Geneticists (AACG), a Special Interest Group of the HGSA, has direct ties with the Royal Australasian College of Physicians (RACP), which is the body that oversees training and accreditation in clinical genetics in Australasia. The AACG advises the RACP on curricula and training requirements. In addition, members of the AACG supervise the clinical training of RACP trainees in clinical genetics. The AACG also oversees a lecture series for clinical genetics trainees. The HGSA hosts a large number of educational events throughout the year to help members undertake continuing professional development. In addition to the Society's Annual Scientific Meeting, members have access to a large number of webinars that are broadcast across Australia and New Zealand. Furthermore, each Branch holds face-to-face educational activities, such as lectures and symposia, for local members.
Opioid rotation or opioid switching is the process of changing one opioid to another to improve pain control or reduce unwanted side effects. This technique was introduced in the 1990s to help manage severe chronic pain and improve the opioid response in cancer patients and non-cancer patients. In order to obtain adequate levels of pain relief, patients requiring chronic opioid therapy may require an increase in the original prescribed dose for a number of reasons, including increased pain or a worsening disease state. Over the course of long-term treatment, an increase in dosage cannot be continued indefinitely as unwanted side effects of treatment often become intolerable once a certain dose is reached, even though the pain may still not be properly managed. One strategy used to address this is to switch the patient between different opioid drugs over time, usually every few months. Opioid rotation requires strict monitoring in patients with ongoing levels of high opioid doses for extended periods of time, since long term opioid use can lead to a patient developing tolerance to the analgesic effects of the drug. Patients may also not respond to the first opioid prescribed to them at all, therefore needing to try another opioid to help manage their pain. A patient's specific response and sensitivity to opioids include many factors that include physiology, genetics and pharmacodynamic parameters, which together determine the amount of pain control and tolerance of a particular opioid.
=== Sovereignty === Favored distribution of vaccines within one or a few select countries, called "vaccine sovereignty", is a criticism of some of the vaccine development partnerships, such as for the AstraZeneca-University of Oxford vaccine candidate, concerning whether there may be prioritized distribution first within the UK and to the "highest bidder" – the United States, which made an advance payment of US$1.2 billion to secure 300 million vaccine doses for Americans, even before the AstraZeneca-Oxford vaccine or a Sanofi vaccine was proved safe or effective. Concerns exist about whether some countries producing vaccines may impose protectionist controls by export restrictions that would stockpile a COVID‑19 vaccine for their own population. The Chinese government pledged in May 2020, that a successful Chinese vaccine would become a "global, public good", implying enough doses would be manufactured for both national and global distribution. Unlike mRNA vaccines, which have to be stored at subzero temperatures, inactivated vaccines from Sinovac and Sinopharm require ordinary refrigeration and may have more appeal in developing countries. In November 2021, the Chinese government pledged to donate in 2022 a further 600 million vaccine doses to Africa, and supply another 400 million through other routes including production by Chinese companies in Africa.
In the case of large pets, such as dogs and cats, freeze-drying is also the best way to capture the animal's expression as it looked in life (another important concern of owners). Freeze-drying equipment is costly and requires much upkeep. The process is also time-consuming; therefore, freeze-drying is generally an expensive method to preserve an animal. The drawback to this method is that freeze-dried mounts are extremely susceptible to insect damage. This is because they contain large areas of dried tissue (meat and fat) for insects to feed upon. Traditional mounts are far less susceptible because they contain virtually no residual tissues (or none at all). Regardless of how well a taxidermy mount is prepared, all taxidermy is susceptible to insect damage. Taxidermy mounts are targeted by the same beetles and fabric moths that destroy wool sweaters and fur coats and that infest grains and flour in pantries.
The SADF believed that a covert sabotage operation was possible, as long as the destruction was not attributable to South Africa and a credible cover story could be used to link the attack to a domestic Angolan movement such as UNITA or the Front for the Liberation of the Enclave of Cabinda (FLEC). An attack on the oil platforms was ruled out, as this was beyond the capabilities of either UNITA or FLEC, so the SADF opted to infiltrate the refinery's oil storage facilities and mine the fuel tanks. The damage incurred would cripple Angola's ability to finance its military operations and give it greater economic incentive to accede to South African demands in the ongoing negotiations rather than risk returning to war. The sabotage mission received the code name Operation Argon, and 15 South African special forces operators deployed to Cabinda by sea in May 1985. They were discovered by a FAPLA patrol during the infiltration attempt, and two of the raiders were shot dead with a third, Captain Wynand Petrus du Toit, being captured. Under interrogation, du Toit confessed that the objective of Argon was to sabotage the storage tanks at Cabinda Gulf. The South African government disavowed du Toit and denied responsibility, but General Viljoen later confirmed the SADF's role in the operation. Consequently, the ceasefire imposed as a result of the Lusaka Accords collapsed, and further peace talks were abandoned. The diplomatic repercussions of Operation Argon's failure were immense.
Sources: en.wikipedia.org
non-coding RNA (ncRNA) Any molecule of RNA that is not ultimately translated into a protein. The DNA sequence from which a functional non-coding RNA is transcribed is often referred to as an "RNA gene". Numerous types of non-coding RNAs essential to normal genome function are produced constitutively, including transfer RNA (tRNA), ribosomal RNA (rRNA), microRNA (miRNA), and small interfering RNA (siRNA); other non-coding RNAs (sometimes described as "junk RNA") have no known function and are likely the product of spurious transcription.
The post-1989 period has been characterised by the privatisation and closure of several former industrial and economic enterprises from the communist period, while corruption has been a major issue in contemporary politics. A National Anticorruption Directorate was formed in the country in 2002. During the 2000s, Romania had one of the highest economic growth rates in Europe and has been referred at times as "the Tiger of Eastern Europe". This has been accompanied by a significant improvement in living standards as the country successfully reduced domestic poverty and established a functional democratic state. However, Romania's development suffered a major setback during the late 2000s' recession leading to a large gross domestic product contraction and a budget deficit in 2009. This led to Romania borrowing from the International Monetary Fund. Worsening economic conditions led to unrest and triggered a political crisis in 2012. Since 2014, Romania launched an anti-corruption effort that led to the prosecution of medium- and high-level political, judicial and administrative offences by the National Anticorruption Directorate. In 2015, massive anti-corruption protests which developed in the wake of the Colectiv nightclub fire led to the resignation of prime minister Victor Ponta. During 2017–2019, in response to measures which were perceived to weaken the fight against corruption, some of the biggest post-1989 protests took place in Romania, with over 500,000 people protesting nationwide.
=== Building blocks for cell-adhesion === By looking at the genome of the Choanoflagellate, "Monosiga brevicollis", scientists have inferred that choanoflagellates play a key role in the development of multicellularity. Nicole King has done work looking at the genome of Monisiga brevicollis, and has found key protein domains that are shared between metazoans and choanoflagellates. These domains play a role in cell signalling and adhesion processes in metazoans. The finding that choanoflagellates also have these genes is an incredible discovery because it was previously thought that only metazoans had genes responsible for cell-cell communication and aggregation. This suggests that these domains play a key role in the origins of multicellularity since it ties a unicellular organism (choanoflagellates) to multicellular organisms (metazoans). It shows that the components required for multicellularity were present in the common ancestor between metazoans and choanoflagellates.
== Clinical significance == There are two congenital disorders of the long bones. In a disorder known as rachitis fetalis anularis the ends of the long bones (epiphyses) are enlarged. Another disorder, rachitis fetalis micromelica, is a deficiency in the growth (as a shortness) of the bones. There is a surgical procedure called distraction osteogenesis which is used to lengthen long bones.
=== Planting === The sacred lotus requires a nutrient-rich and loam soil. In the beginning of the summer period (from March until May in the northern hemisphere), a small part of rhizome with at least one eye is either planted in ponds or directly into a flooded field. It can also be propagated via seeds or buds. Furthermore, tissue culture is a promising propagation method for the future to produce high volumes of uniform, true-to-type, disease-free materials. The first step of cultivation is to plough the dry field. One round of manure is applied after ten days, before flooding the field. To support a quick initial growth, the water level is relatively low and increases when plants grow. Then a maximum of approximately 4,000 per hectare (1,600/acre) with grid spacing of 1.2 by 2 metres (3 ft 11 in × 6 ft 7 in) are used to plant directly into the mud 10–15 cm (3+7⁄8–5+7⁄8 in) below the soil surface.
Sources: en.wikipedia.org
Yes, the World Anti-Doping Agency classifies AOD-9604 as a prohibited peptide hormone and related substance. Its use by athletes is banned under the relevant anti-doping code.
Confirmatory detection typically uses liquid chromatography with mass spectrometry. Immunoassays may be used for screening, but mass spectrometry provides structural confirmation.
No widely approved therapeutic indication exists for AOD-9604. It has been investigated in clinical studies, but regulatory approvals for general medical use are not established.
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.